- Anthony J Dixon, professor1
- 1Australasian College of Cutaneous Oncology, Belmont, VIC 3216, Australia
Ten years ago we hoped sentinel lymph node biopsy (SNB) “treatment” would prolong life for patients with melanoma. Then the first Multicenter Selective Lymphadenectomy Trial (MSLT-1) failed to show a five year survival advantage.1 Now we talk of the SNB “test” offering some patients a more accurate survival prediction.
We advise …